GC
VANI icon

Guggenheim Capital’s Vivani Medical VANI Stock Holding History

Guggenheim Capital’s Portfolio VANI Stock Details VANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-433
Closed -$20K – 2609
2018
Q1 		$20K Buy
433
+3
+0.7% +$133 ﹤0.01% 2745
2017
Q4 		$20K Sell
430
-54
-11% -$1.79K ﹤0.01% 2673
2017
Q3 		$14K Buy
+484
New +$13.5K ﹤0.01% 2768

Other funds holding VANI

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
GWS
Glassman Wealth Services Vienna, Virginia $736M AUM 17.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Guggenheim Capital's VANI Position: Q2 2018 in Review

Guggenheim Capital sold out of Vivani Medical (VANI) in Q2 2018, closing a stake of 433 shares — an estimated $20K sold.

Guggenheim Capital first reported a position in VANI in Q3 2017 and held it in 3 quarters. The position peaked at $20K in Q1 2018. 39 funds tracked by Wall St. Rank hold VANI as of Q2 2018.

  • Guggenheim Capital reported no remaining Vivani Medical position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 433 Vivani Medical shares in Q2 2018, an estimated $20K.
  • Guggenheim Capital first reported a position in Vivani Medical in Q3 2017 and held it in 3 quarters.
  • Guggenheim Capital's Vivani Medical position peaked at $20K in Q1 2018.
  • 39 funds tracked by Wall St. Rank held Vivani Medical as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.